Search

Your search keyword '"Giorgino, R."' showing total 22 results
Start Over Author "Giorgino, R." Publisher elsevier bv
22 results on '"Giorgino, R."'

4. Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold

Author

Chaturvedi, Nish, Bandinelli, Simona, Mangili, Ruggero, Penno, Guiseppe, Rottiers, Raoul E., Fuller, John H., Karamanos, B., Kofinis, A., Petrou, K., Giorgino, R., Giorgino, F., Picca, G., Angarano, A., De Pergola, G., Ionescu-Tirgoviste, C., Coszma, A., Songini, M., Casu, A., Pedron, M., Fossarello, M., Ferriss, J. B., Grealy, G., Keefe, D. O., White, A., Cleary, P. E., Toeller, M., Arden, C., Rottiers, R., Tuyttens, C., Priem, H., Ebeling, P., Kylliainen, M., Kyostio-Renvall, T., Idzior-Walus, B., Sieradzki, J., Cyganek, K., Lemkes, H. H. P. J., Roest, C., Nunes-Correa, J., Rogado, M. C., Gardete-Correia, L., Cardoso, M. C., Michel, G., Wirion, R., Cardillo, S., Pozza, G., Mangili, R., Asnaghi, V., Lattanzio, Rosangela, Galardi, G., Standl, E., Schaffler, B., Brand, H., Harms, A., Ben Soussan, D., Verier-Mine, O., Fuller, J. H., Holloway, J., Asbury, L., Betteridge, D. J., Cathelineau, G., Bouallouche, A., Villatte Cathelineau, B., Santeusanio, F., Rosi, G., D’ Alessandro, V., Cagini, C., Navalesi, R., Penno, G., Bandinelli, S., Miccoli, R., Ghirlanda, G., Saponara, C., Cotroneo, P., Manto, A., Minnella, A., Ward, J. D., Tesfaye, S., Eaton, S., Mody, C., Porta, M., Perin, P. Cavallo, Borra, M., Giunti, S., Papazoglou, N., Manes, Gianfranco, Muggeo, M., Iagulli, M., Irsigler, K., Abrahamian, H., Walford, S., Wardle, E. V., Sinclair, J., Hughes, S., Roglic, G., Metelko, Z., Resman, Z., Sjolie, A. -. K., Chaturvedi, N., Ferriss, B., Webb, D., Viberti, G. -. C., Swaminathan, R., Lumb, P., Collins, A., Sankaralingham, S., Aldington, S., Mortemore, T., and Lipinski, H.

Subjects
Albuminuria, Blood sugar control, Cardiovascular disease, Insulin resistance, Renal disease, Adolescent, Adult, Blood Glucose, Body Constitution, Cohort Studies, Diabetes Mellitus, Type 1, Differential Threshold, Disease Progression, Europe, Female, Follow-Up Studies, Humans, Incidence, Insulin Resistance, Male, Middle Aged, Prospective Studies, Reference Values, Risk Factors, Triglycerides, Nephrology, endocrine system diseases, urologic and male genital diseases, Gastroenterology, Waist–hip ratio, Proteinuria, Settore MED/30 - MALATTIE APPARATO VISIVO, female genital diseases and pregnancy complications, medicine.symptom, Type 1, medicine.medical_specialty, Internal medicine, Diabetes mellitus, Diabetes Mellitus, medicine, Risk factor, Glycemic, Type 1 diabetes, business.industry, nutritional and metabolic diseases, medicine.disease, Endocrinology, Microalbuminuria, business
Abstract

Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold.BackgroundThe occurrence of microalbuminuria in type 1 diabetes is strongly predictive of renal and cardiovascular disease and is still likely to occur despite improvements in glycemic control. A better understanding of microalbuminuria is required to inform new interventions. We determined the incidence and risk factors for microalbuminuria [albumin excretion rate (AER) 20 to 200 μg/min] in the EURODIAB Prospective Complications Study.MethodsThis is a seven-year follow-up (between 1988 and 1991) of 1134 normoalbuminuric men and women (aged 15 to 60) with type 1 diabetes from 31 European centers. Risk factors and AER were measured centrally.ResultsThe incidence of microalbuminuria was 12.6% over 7.3 years. Independent baseline risk factors were HbA1c (7.1 vs. 6.2%, P = 0.0001) and AER (9.6 vs. 7.8 μg/min, P = 0.0001) and, independent of these, fasting triglyceride (0.99 vs. 0.88 mmol/L, P = 0.01), low-density lipoprotein cholesterol (3.5 vs. 3.2 mmol/L, P = 0.02), body mass index (24.0 vs. 23.4 kg/m2, P = 0.01), and waist to hip ratio (WHR; 0.85 vs. 0.83, P = 0.009). Triglyceride and WHR risk factors were nearly as strong as AER in predicting microalbuminuria (standardized regression effects of 1.3 for triglyceride and WHR and 1.5 for AER). Blood pressure at follow-up, but not at baseline, was also raised in those who progressed. There was no evidence of a threshold of HbA1c on microalbuminuria risk.ConclusionsThe incidence of microalbuminuria in patients with type 1 diabetes remains high, and there is no apparent glycemic threshold for it. Markers of insulin resistance, such as triglyceride and WHR, are strong risk factors. Systemic blood pressure is not raised prior to the onset of microalbuminuria.

Published
2001

12. Continuous subcutaneous glucose monitoring in diabetic patients: A multicenter evaluation

Author

Maran, A, primary, Crepaldi, C, additional, Tiengo, A, additional, Grassi, G, additional, Vitali, E, additional, Pagano, G, additional, Bistoni, S, additional, Calabrese, G, additional, Santeusanio, F, additional, Leonetti, F, additional, Ribaudo, M, additional, Di Mario, U, additional, Annuzzi, G, additional, Genovese, S, additional, Riccardi, G, additional, Previti, M, additional, Cucinotta, D, additional, Giorgino, F, additional, Perrini, S, additional, Giorgino, R, additional, Poscia, A, additional, and Varalli, M, additional

Published
2000
Full Text
View/download PDF

14. Retinopathy and Vision Loss in Insulin-dependent Diabetes in Europe

Author

Sjølie, Anne Katrin, primary, Stephenson, Judith, additional, Aldington, Steve, additional, Kohner, Eva, additional, Janka, Hans, additional, Stevens, Lynda, additional, Fuller, John, additional, Karamanos, B., additional, Tountas, C., additional, Kofinis, A., additional, Petrou, K., additional, Katsilambros, N., additional, Cignarelli, M., additional, Giorgino, R., additional, De Geco, M.L., additional, Ramunni, I., additional, Ionescu-Tirgoviste, C., additional, Iosif, C.M., additional, Pitei, C., additional, Buligescu, S., additional, Tamas, G., additional, Kerenyi, Z., additional, Ahmed, A.M., additional, Toth, J., additional, Kempler, P., additional, Muntoni, S., additional, Songini, M., additional, Stabilini, M., additional, Fossarello, M., additional, Pintus, S., additional, Ferriss, B., additional, Cronin, C.C., additional, Toeller, M., additional, Klischan, A., additional, Forst, T., additional, Gries, F.A., additional, Rottiers, R., additional, Priem, H., additional, Ebeling, P., additional, Sinisalo, M., additional, Koivisto, V.A., additional, Idzior-Walus, B., additional, Solnica, B., additional, Szopinska-Ciba, L., additional, Solnica, K., additional, Krans, H.M.J., additional, Lemkes, H.H.P.J., additional, Jansen, J.J., additional, Nunes-Cornea, J., additional, Boavida, J., additional, Michel, G., additional, Wirion, R., additional, Boulton, A.J.M., additional, Ashe, H., additional, Fernando, D.J.S., additional, Pozza, G., additional, Slaviero, G., additional, Comi, G., additional, Fattor, B., additional, Bandello, F., additional, Mehnert, H., additional, Nuber, A., additional, Janka, H., additional, Ben Soussan, D., additional, Fallas, M.C., additional, Fallas, P., additional, Jepson, E., additional, McHardy-Young, S., additional, Fuller, J.H., additional, Betteridge, D.J., additional, Milne, M., additional, Crepaldi, G., additional, Nosadini, R., additional, Cathelineau, G., additional, Villatte Cathelineau, B., additional, Jellal, M., additional, Grodner, N., additional, Gervais Feiss, P., additional, Santeusanio, F., additional, Rosi, G., additional, Ventura, M.R.M., additional, Cagini, C., additional, Marino, C., additional, Navalesi, R., additional, Penno, G., additional, Miccoli, R., additional, Nannipieri, M., additional, Manfredi, S., additional, Ghirlanda, G., additional, Cotroneo, P., additional, Manto, A., additional, Teodonio, C., additional, Minnella, A., additional, Ward, J.D., additional, Tesfaye, S., additional, Mody, C., additional, Rudd, C., additional, Molinatti, G.M., additional, Vitelli, F., additional, Porta, M., additional, Pagano, G.F., additional, Cavallo Perin, P., additional, Estivi, P., additional, Sivieri, R., additional, Carta, Q., additional, Petraroli, G., additional, Papazoglou, N., additional, Manes, G., additional, Triantaphyllou, G., additional, Ioannides, A., additional, Muggeo, M., additional, Cacciatori, V., additional, Bellavere, F., additional, Galante, P., additional, Gemma, M.L., additional, Irsigler, K., additional, Abrahamian, H., additional, Gurdet, C., additional, Hornlein, B., additional, Willinger, C., additional, Walford, S., additional, Wardle, E.V., additional, Roglic, G., additional, Resman, Z., additional, Metelko, Z., additional, and Skrabalo, Z., additional

Published
1997
Full Text
View/download PDF

22. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient study

Author

Alberto Angeli, A Dovio, Andrea Giustina, Giuseppe Guglielmi, Daniela de Feo, Giovanni Capelli, Sandro Giannini, Ruben Giorgino, Luigi Moro, Angeli, A, Guglielmi, G, Dovio, A, Capelli, G, DE FEO, D, Giannini, S, Giorgino, R, Moro, L, and Giustina, Andrea

Subjects
medicine.medical_specialty, Histology, Bone density, Physiology, Cross-sectional study, Endocrinology, Diabetes and Metabolism, Osteoporosis, Lumbar vertebrae, Asymptomatic, Article, Polymyalgia rheumatica, Absorptiometry, Photon, Bone Density, Risk Factors, Surveys and Questionnaires, Internal medicine, Outpatients, Epidemiology, Prevalence, medicine, Humans, Glucocorticoids, Osteoporosis, Postmenopausal, Aged, Retrospective Studies, Lumbar Vertebrae, business.industry, Retrospective cohort study, Middle Aged, medicine.disease, Surgery, Postmenopause, Epidemiologic Studies, Cross-Sectional Studies, Logistic Models, medicine.anatomical_structure, Italy, Linear Models, Quality of Life, Spinal Fractures, Female, medicine.symptom, business
Abstract

Glucocorticoid (GC)-induced osteoporosis mostly affects trabecular bone of vertebrae. Only 30% of vertebral fractures are symptomatic, yet both clinical and radiological vertebral fractures have been associated with increased mortality and morbidity. The aims of this cross-sectional, outpatient-based study were to measure the prevalence of asymptomatic vertebral fractures in a large sample of post-menopausal women given GCs for different diseases; to compare prevalence of asymptomatic vertebral fractures according to disease, GC treatment and major risk factors; and to assess the quality of life in GC users with and without asymptomatic vertebral fractures. 551 patients referring to 39 centers as outpatients for their programmed follow-up and satisfying the inclusion criteria were included in the analysis. Each patient underwent structured medical interview (including dose and duration of GC therapy, major risk factors for osteoporosis, the quality of life questionnaire of the European Foundation for Osteoporosis (QUALEFFO) and a back function score questionnaire), thoraco-lumbar radiographs and subsequent morphometry; for 253 and 437 patients, respectively, lumbar spine bone mineral density (BMD) assessed by dual energy X-ray absorptiometry and calcaneal bone stiffness assessed by quantitative ultrasonometry were available. The prevalence of asymptomatic vertebral fractures resulted >37%, with >14% of patients having two or more asymptomatic vertebral fractures and was much higher than that found in epidemiological studies on healthy women. Distribution of asymptomatic vertebral fractures along the spine showed a bimodal pattern, with two peaks at T7 and T11. The prevalence of asymptomatic vertebral fractures clearly increased with age. Differences in prevalence among diseases were evidenced. When controlled for age, GC cumulative dose, duration of therapy and personal history of fractures, the adjusted prevalences were 30.77% for systemic lupus erythematosus, 33.78% for rheumatoid arthritis, 37.78% for asthma/chronic obstructive pulmonary disease, 43.20% for polymyalgia rheumatica and 43.36% for diseases grouped as "other vasculitides/connective tissue diseases". No significant association was found with GC cumulative dose and duration of therapy. Established risk factors for osteoporosis (except for age, years since menopause and personal history of fractures), lumbar spine BMD, calcaneal stiffness and QUALEFFO score were not associated with number and severity of asymptomatic vertebral fractures. Underlying disease is likely to contribute to the risk of fracture, but disease by itself could not be dissected from GC regimen. Vertebral fractures should be looked for carefully in all post-menopausal women receiving long-term systemic GCs since they can be asymptomatic and are scarcely predictable.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results